Fixed low-dose combination therapy for hypertension

Current Hypertension Reports

Volumn 4, Issue 4, 2002, Pages 298-306

  Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; HUMAN; HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERTENSION;

EID: 0036691484     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-996-0008-9     Document Type: Article

References (49)

1. Neal B, MacMahon S: An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization- International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Clin Exp Hypertens 1999, 21: 517-529.
2. Marques-Vidal P, Tuomilehto J: Hypertension awareness, treatment and control in the community: is the "rule of halves" still valid? J Hum Hypertens 1997, 1 1: 213-223.
3. Murray CJ, Lopez AD: Evidence-based health policylessons from the Global Burden of Disease Study. Science 1996, 274: 740-743.
4. Brunner HR, Menard J, Waeber B, et al.: Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990, 8: 3-11.
5. Epstein M, Bakris G: Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996, 156: 1969-1978.
6. Waeber B, Brunner HR: Low-dose combinations versus monotherapies in the treatment of hypertension. J Hypertens 1997, 15(Suppl 2): 17-20.
7. Moser M, Prisant LM: Low-dose combination therapy in hypertension. Am Fam Physic 1997, 56: 1275-1276.
8. Neutel JM, Smith DH, Weber MA: Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001, 14: 286-292.
9. Waeber B, Brunner HR: Rationale for the use of very-low-dose combinations as first-line treatment of hypertension. J Hypertens 2001, 19(Suppl 4): S3-S8.
10. Sever P: The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? J Hum Hypertens 1995, 9: S33-S36.
11. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328: 914-921.
12. Materson BJ, Reda DJ, Cushman WC: Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995, 8: 189-192.
13. Waeber G, Beck G, Waeber B, et al.: Comparison of betaxolol with verapamil in hypertensive patients: discrepancy between office and ambulatory blood pressures. J Hypertens 1988, 6: 239-245.
14. Bidiville J, Nussberger J, Waeber G, et al.: Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988, 11: 166-173.
15. Attwood S, Bird R, Burch K, et al.: Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994, 12: 1053-1060.
16. Swales JD: Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999, 138: 231-237.
17. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 1999, 34: 381-385.
18. Shrivastava S, Kochar MS: The need to lower systolic blood pressure. Curr Hypertens Rep 2000, 2: 433-440.
19. Staessen JA, Gasowski J, Wang JG, et al.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355: 865-872.
20. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351: 1755-1762.
21. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157: 2413-2446.
22. 1999 World Health Organization-International Society of Hypertension: Guidelines for the management of hypertension. J Hypertens 1999, 17: 151-183.
23. Dickerson CJE, Hingorani AD, Ashby MJ, et al.: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353: 2008-2013.
24. Morgan TO, Anderson AI, MacInnis RJ: ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001, 14: 241-247.
25. Lip GY, Beevers GD: Doctors, nurses, pharmacists and patients. The Rational Evaluation and Choice in Hypertension (REACH) survey of hypertension care delivery. Blood Press 1997, 6(Suppl 1): 6-10.
26. Dusing R, Weisser B, Mengden T, Vetter H: Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press 1998, 7: 313-315.
27. Ambrosioni E, Leonetti G, Pessina AC, et al.: Patterns of hypertension management in Italy: results of a pharmacoepi-demiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000, 18: 1691-1699.
28. Fagan TC: Remembering the lessons of basic pharmacology. Arch Intern Med 1994, 154: 1430-1431.
29. Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 2000, 355: 637-645.
30. Brunner HR, Nussberger J, Waeber B: Responsiveness of renin secretion: a key mechanism in the maintenance of blood pressure. J Hypertens 1986, 4(Suppl 4).
31. Kiowski W Erne P, Bertel O, et al.: Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol 1986, 7: 344-348.
32. de Leeuw P, Kroon A: Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension. J Hypertens 1997, 15(Suppl 2): 39-42.
33. Materson BJ, Reda DJ, Cushman WC, Henderson WG: Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens 1995, 9: 791-796.
34. Cuspidi C, Lonati L, Sampieri L, et al.: Blood pressure control in a hypertension hospital clinic. J Hypertens 1999, 17: 835-841.
35. Gradman AH, Cutler NR, Davis PJ, et al.: Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997, 79: 431-435.
36. Gustafsson D, Grande PO, Borgstrom P, Lindberg L: Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol 1988, 12: 413-422.
37. Fenickel RR, Lipicky RJ: Combination products as first-line pharmacotherapy. Arch Intern Med 1994, 154: 1429-1430.
38. Frishman WH, Bryzinski BS, Coulson L, et al.: A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994, 154: 1461-1468.
39. Papademetriou V, Prisant LM, Neutel JM, Weir MR: Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. Am J Cardiol 1998, 81: 1363-1365.
40. Waeber B, Detry JM, Dahlof B, et al.: Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy? Am J Hypertens 1999, 12: 915-920.
41. Morgan T, Anderson A, Mauri J, Bertram D: Low-dose combination therapy (perindopril, indapamide) compared with irbesartan monotherapy. J Hypertens 2001, 19(Suppl 2): S235.
42. Laurent S: Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. J Hypertens 2001, 19(Suppl 4): S9-S14.
43. Waeber B: A review of irbesartan in antihypertensive therapy: comparison with other agents? Curr Ther Res 2001, 62: 505-523.
44. Waeber B: A review of the clinical experience with the angiotensin II receptor antagonist irbesartan. Cardiovasc Drug Rev 2000, 18: 103-126.
45. Waeber B, Burnier M, Brunner HR: Compliance with antihypertensive therapy. Clin Exp Hypertens 1999, 21: 5-6.
46. Ambrosioni E: Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics 2001, 19: 337-347.
47. Weinberger MH: Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985, 7: S52-S55.
48. MacKay JH, Arcuri KE, Goldberg AI, et al.: Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996, 156: 278-285.
49. Bakris GL, Williams B: Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995, 13: S95-S101.